Business Context and Reporting Period
This Form 8-K Current Report was filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on August 14, 2020, regarding events occurring on August 11, 2020. The registrant is a Delaware corporation and an emerging growth company. The filing discloses the entry into a material definitive consulting agreement with Blue Ox Healthcare Partners, LLC ("Blue Ox") to advance market strategy and reimbursement efforts for the Obalon Balloon System.
Key Financial Metrics and Transaction Details
The filing details a specific financial commitment rather than periodic financial performance metrics such as revenue or cash flow.
- Consulting Fees: A cash fee of $50,000 per month for an initial six-month period, totaling $300,000.
- Payment Schedule: Payable in two equal installments; the first was paid upon execution, and the second is due on the first day of the fourth month.
- Equity Compensation: Issuance of a warrant to purchase up to 100,000 shares of common stock.
- Warrant Terms: Exercise price of $0.8285 per share (a 15% premium to the 10-day average closing price); exercisable immediately; expires August 10, 2025.
- Future Compensation: Post-initial term compensation to be negotiated or continue at $50,000 per month.
Material Changes and Agreements
The primary material change is the execution of the Consulting Agreement and the associated warrant issuance. Key provisions include:
- Scope of Services: Blue Ox will secure health plan agreements for outcomes studies, advise on coverage and reimbursement strategies, and facilitate reimbursement agreements for the Obalon Balloon System.
- Term and Termination: The agreement has a one-year term with automatic one-month renewals. Either party may terminate with 30 days' written notice or upon a change of control.
- Pro Rata Adjustment: If the agreement is terminated within six months, the warrant share count will be reduced on a pro rata basis.
- Additional Rights: Blue Ox has rights to additional milestone-based warrants, piggyback registration rights, and participation rights in the Company's first securities offering following the agreement date.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary on future earnings. The strategic outlook focuses on expanding the clinical evidence base with health economic analysis and securing reimbursement agreements. Risks associated with the transaction include potential dilution from the warrant exercise and the contingent nature of future milestone-based warrants. The warrant issuance was exempt from registration under Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the current cash position to ensure the $300,000 total fee obligation is covered, noting the second installment is due in the fourth month.
- Review the full text of the Consulting Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific milestone definitions and termination clauses.
- Assess the potential dilution impact of the 100,000 warrant shares and any future milestone warrants.
- Monitor the Company's progress in securing health plan agreements for outcomes studies as a key performance indicator of the consulting engagement.